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system white matter of SJL mice infected with the BeAn strain
of Theiler’s murine encephalomyelitis virus (TMEV) revealed a
significant reduction of miR-219, a critical regulator of myelin
assembly and repair. Restoration of miR-219 expression by
intranasal administration of a synthetic miR-219 mimic before
disease onset ameliorates clinical disease, reduces neurogliosis,
and partially recovers motor and sensorimotor function by
negatively regulating proinflammatory cytokines and virus
RNA replication. Moreover, RNA sequencing of host lesions
showed that miR-219 significantly downregulated two genes
essential for the biosynthetic cholesterol pathway, Cyp51
(lanosterol 14-a-demethylase) and Srebf1 (sterol regulatory
element-binding protein-1), and reduced cholesterol biosyn-
thesis in infected mice and rat CG-4 glial precursor cells in
culture. The change in cholesterol biosynthesis had both
anti-inflammatory and anti-viral effects. Because RNA viruses
hijack endoplasmic reticulum double-layered membranes to
provide a platform for RNA virus replication and are depen-
dent on endogenous pools of cholesterol, miR-219 interference
with cholesterol biosynthesis interfered virus RNA replication.
These findings demonstrate that miR-219 inhibits TMEV-
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MicroRNAs (miRs) are small noncoding RNAs that regulate a myriad
of biological processes by controlling gene expression.1 Their dysre-
gulation is associated with pathological conditions, suggesting the
usefulness of synthetic miR mimics to restore or inhibit the levels
of endogenous miRs.2 CNS virus infections are of increasing interest
as etiological agents causing neurological deficits in humans by
directly targeting neuroglia3 or as a bystander effect of virus-induced
pathology.4 Although miR-based therapies have been applied suc-
cessfully to systemic virus infections and are under preclinical730 Molecular Therapy Vol. 26 No 3 March 2018 ª 2018 The Americanstudies,5,6 little is known about their usefulness in the context of
CNS virus infections and CNS repair.
Theiler’s murine encephalomyelitis virus (TMEV) produces chronic
inflammation, together with a combination of oligodendrocyte
(OL) death and immune-mediated demyelination, in susceptible
mouse strains.7 The low-neurovirulence TMEV BeAn strain provides
a relevant experimental animal model for multiple sclerosis (MS), the
most common demyelinating disease in adults.8,9 Unlike the induc-
tion of demyelination by either chemical (lysolecithin and cuprizone)
or immunological (experimental allergic encephalomyelitis [EAE])
means, TMEV-induced demyelination is the result of virus infection
in its natural host. Demyelination in this setting requires persistence
with a continuously replicating virus in an immunocompetent host to
produce its immunopathology. Thus, TMEV infection in mice is an
experimental model to assess candidate treatments for neurological
dysfunction and myelin repair.
Gain- and loss-of-function studies have identified miR-219 as a key
regulator of OL development, myelination, and remyelination.10–12
miR-219 participates in OL maturation through repression of Pdgfra,
Hes5, Sox6, Etv5, and Lingo1, which inhibit OL differentiation,11–13
and through cooperative interactions with miR-338 during remyeli-
nation.13 The physiological significance of miR-219 in remyelinationSociety of Gene and Cell Therapy.
Figure 1. Effects of BeAn Infection on OL-Related
miRNAs
(A and B) miRNA expression by qPCR of OL-related
miRNAs, miR-17, miR-19b, miR-138, miR-219,
miR-338, and astrocyte-related miR-146, in white
matter of TMEV-infected mice at 30 days pi (A) and
90 days pi (B). One-way ANOVA followed by Dunnett’s
test: (A) F (6, 30) = 5.472, *p < 0.05 and **p < 0.01
(n = 3 per group); and (B) F (6, 32) = 4.346, *p < 0.05,
**p < 0.01, and ***p < 0.001 (n = 3 per group). (C)
miRNA expression by qPCR of OL-related miRNAs:
miR-17, miR-19b, miR-138, miR-219, miR-338, and
astrocyte-related miR-146 in neural stem cells differ-
entiated for 2 days (n = 3). (D) Cell viability (WST-1
assay) of CG-4 cells at 24 hr after TMEV infection
(10 MOI) under proliferating (PDGFAA) or differentiating
conditions (1 div or 3 div). MOI, multiplicity of infection;
div, days in vitro. (E) Cell viability in differentiated (3 div)
CG-4 cells treated with miR-219 or scrambled miR
(50 nM) before or after TMEV infection (10 MOI); one-
way ANOVA followed by Dunnett’s test, F (2, 6) =
10.65, *p < 0.05 (n = 3 per group). Data are expressed
as mean ± SEM.
www.moleculartherapy.orgis further supported by the finding of low miR-219 levels in non-
remyelinating MS lesions.14 These observations point to the promise
of miR-219 treatment in restoring miR function and ameliorating
myelin pathology. Previously, we successfully used miR-219 mimics
to reduce chemical and inflammatory demyelination in lysolecithin
and EAE models,13 underscoring the potential utility of miR-219
for treatment of other types of demyelination.15,16
Here, we analyzed the therapeutic effects of miR-219 in a virus-
induced demyelinating model. Following intranasal administration
of miR-219 in TMEV-infected mice, we found significant reduction
of clinical signs, virus persistence (virus genome copy numbers),
neuroglia activation, proinflammatory cytokine levels, and demyelin-
ation. RNA sequencing of expressed host genes demonstrated that
miR-219 potentiates transcriptional changes in cholesterol-related
genes, leading to reduced levels of this lipid. Because virus replication
relies on hijacking cholesterol biosynthesis and trafficking of host cell
endogenous pools as well as remodeling intracellular membranes, i.e.,
the virus replication organelles or viroplasm,17 treatment with
miR-219 may interfere with virus RNA replication through downre-
gulation of cholesterol synthesis. Our findings show that miR-219
administration lessens pathological changes by reducing the CNS vi-
rus loads and favoring myelin repair.13
RESULTS
BeAn Virus Infection Is Associated with Decreased miR-219
Levels
To determine whether BeAn virus infection modifies OL-related
miRNA expression, white matter was isolated from the brains ofmice at 30 (disease onset) and 90 (chronic demyelination) days post
infection (pi) and analyzed by qPCR. Several OL-related miRNAs,
including miR-17, miR-19b, miR-138, miR-219, and miR-338, were
downregulated during early/acute (Figure 1A) and late/chronic (Fig-
ure 1B) stages of infection. Further experiments showed that after infec-
tion, miR-19b, miR-138, and miR-219 were substantially downregu-
lated in differentiated neural progenitors isolated from the SJL mouse
brain (Figure 1C). Of the downregulated miRs, miR-219 was of partic-
ular interest because it is downregulated inMS lesions andnecessary for
OL differentiation, myelination, and remyelination.11–13 CG-4 cells,
which were susceptible to BeAn infection (Figure 1D), were protected
from infection when pre-treated with the miR-219 mimic (Figure 1E).
In Vivo miR-219 Treatment Decreases Disease Severity
The therapeutic effects of miR-219 mimics were assessed in virus-in-
fected mice treated weekly during 22 weeks via an intranasal route, a
non-invasive drug administration method18–20 (Figure 2A). To study
biodistribution, Cy3-labeled miR mimics were first administered to
naive SJL mice and analyzed by confocal microscopy. Cy3-labeled
miR was distributed throughout the CNS, from the frontal cortex
to spinal cord, with a gradient decreasing in a rostral-caudal direction
(Figures S1A, S1B, and S1D), and taken up by multiple cell types,
including astrocytes, microglia, neurons, and OLs (Figure S1C).
Cumulative disease scores of infected mice that received weekly doses
of miR-219 for 22 weeks beginning before disease onset (Figure 2A)
were significantly lower than those in mice treated with vehicle or
scrambled miR (Figures 2B and 2C), indicating that treatment with
miR-219 reduces disease severity in mice with demyelination.Molecular Therapy Vol. 26 No 3 March 2018 731
Figure 2.miR-219Decreases Disease Severity, Improves Sensorimotor Functions andPeripheral Nerve Conduction, but Not Balance orMotor Coordination
(A) Experimental design of weekly supplementation therapy by intranasal delivery of synthetic miR-219 mimics. (B) Temporal progression of cumulative clinical score
over treatment period in healthy animals (control) and mice with chronic demyelination treated with vehicle (TMEV+veh), scrambled miR (TMEV+miR-scr), or miR-219
(TMEV+miR-219). Two-way ANOVA followed by Bonferroni’s test, F (3, 1,033) = 9,016, **p < 0.01 and ***p < 0.001 (n = 7 to 8 per group). (C) Cumulative clinical score over
22 weeks of treatment. One-way ANOVA followed by Tukey’s test, F (3, 1,078) = 281.3, ***p < 0.001 (n = 7 to 8 per group). Cumulative clinical score was calculated as the
sum of the clinical score and body weight loss (see Materials and Methods). Data are expressed as mean ± SEM. (D) Clasping score: one-way ANOVA followed by Tukey’s
test, F (3, 512) = 11.45, **p < 0.01 and ***p < 0.001. (E and F) Balance andmotor coordination analyzed by rotarod test: latency to fall (sec) in the experimental groups treated
for 6 weeks (E) or 22 weeks (F). One-way ANOVA followed by Tukey’s test in (F), F (3, 80) = 16.43, **p < 0.01. (G–I) Gait abnormalities assessed by footprint analysis: length
(cm) of stride (G), sway (H), and stance (I) as an indication of motor coordination. (J) Motor nerve conduction velocity (MCV) (m/s) was determined on sciatic nerves. One-way
(legend continued on next page)
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www.moleculartherapy.orgAssessment of motor and somatosensory functions using a battery of
behavioral tests21–23 in miR-219-treated mice revealed significant
restoration of muscle and motor strength, as measured by reflexive
hind limb clasping (Figure 2D), whereas coordination determined
by the rotarod test (Figures 2E and 2F) and by the footprint test
were not improved (Figures 2G–2I). Motor nerve function, as
measured by motor conduction velocities in the sciatic nerve,24 also
recovered in miR-219-treated mice to that of healthy control nerves
(Figure 2J). Somatosensory function, as determined using hot plate
and tape removal tests, showed significant normalization toward con-
trol levels in miR-219-treated mice (Figures 2K and 2L). These results
indicate that long-term miR-219 treatment improves CNS and pe-
ripheral nervous system (PNS) function and ameliorates many
clinical signs of disease, althoughmotor coordination did not recover.
The nature of this difference might reflect a preferential effect of ther-
apeutic miR-219 on sensory tracts (dorsal white matter) over that on
motor tracts (ventral white matter) (Figure S1B).
miR-219 Reduces Demyelination and Increases OL Numbers
To test whether improvement in clinical disease and neurological
function correlates with pathological changes, sections of thoracic
spinal cord, the site of greatest lesion severity, were plastic embedded,
semithin sectioned, stained with toluidine blue, and analyzed for
myelin structure (Figures 3A and 3B). The demyelinated axon density
in dorsal and ventral white matter was significantly lower in infected
mice treated with miR-219 compared to those treated with vehicle or
scrambled miR. Dorsal white matter exhibited less demyelinated
axons (20%) than ventral white matter (40%) (Figures 3C and
3D). In addition, myelin thickness (g ratio) in the dorsal and ventral
white matter significantly normalized after miR-219 treatment (Fig-
ures 3E and 3F). In addition, Luxol fast blue staining (Figure 3G)
demonstrated that miR-219 treatment reduced areas of demyelin-
ation by 50% compared to infected mice treated with vehicle or
scrambled miR (Figure 3H).
Confocal microscopy showed that miR-219 treatment improved
expression of MBP (Figure 4A) without altering the number of neu-
rons (NeuN+ cells) (Figures 4A and 4B) and significantly normalized
the number of CC1+ OLs (Figures 4C and 4D). Expression analyses
also revealed significantly greater levels of MBP proteins (Figures
4E and 4F), reduced numbers of OL precursors (OPCs) expressing
PdgframRNA (Figure 4G and 4H), and PDGFRa protein levels (Fig-
ures 4I and 4J) in miR-219-treated mice than vehicle- or scrambled
miR-treated mice. However, Olig2 mRNA cell density was not
affected in miR-219-treated mice (Figures 4K and 4L). Thus, weekly
treatment with miR-219 reduced the relative amounts PDGFRa pro-
tein and PdgframRNA cells, which could in part be explained by fluc-
tuations in their half-life and turnover,25 with increased numbers ofANOVA followed by Tukey’s test, F (3, 22) = 9.95, **p < 0.01 and ***p < 0.001. (K and L
withdraw hindlimbs or forelimbs. One-way ANOVA followed by Tukey’s test: (I) F (3, 24
included controls (Ct) and mice with chronic demyelination treated with vehicle (TME
expressed as the mean ± SEM, n = 7 to 8 mice per group.mature CC1+ oligodendrocytes in TMEV mice. Together, these re-
sults indicate that miR-219 treatment lessens disease severity and
neurological dysfunction by reducing the amount of demyelination.
miR-219 Reduces Microglia Activation, Astrogliosis, and
Fibrinogen Leakage in Parallel to Reduction of Virus Copy
Numbers
Inflammation is an important component of virus-induced demyelin-
ation.26 To determine whether miR-219 treatment changes the in-
flammatory process, the status of resident microglia was assessed.
The robust activation of microglia, which showed amoeboid
morphology and increased cell density induced by infection, wasmiti-
gated by miR-219 compared to vehicle or scrambled miR (Figures
S2A and 5D). Activation of astrocytes as measured by immunoblot-
ting for Serpina3n27 (Figures 5A and 5B) as well as the high expres-
sion of GFAP (Figures S2B, 5A, and 5C) were also significantly
reduced in infected mice after treatment with miR-219. Leakage of
fibrinogen into the CNS parenchyma28 was also reduced (Figure S2C)
in miR-219-treated mice, resulting in noticeably smaller areas of
fibrinogen immunoreactivity.
Analysis of spinal cords to test whether pleiotropic effects of miR-219
in reducing themagnitude of virus-induced demyelination and gliosis
involved changes in virus load by qPCR29 revealed significantly fewer
BeAn virus copies in infected mice with miR-219 than did mice
treated with vehicle or scrambled miR (Figure 5E). Confocal micro-
scopy of antibody-stained BeAn virus antigens revealed significant
reduction of immunoreactivity in miR-219-treated mice compared
to controls (Figures S2D and 5F), consistent with the effect of miR-
219 on BeAn virus RNA replication and its persistence in the CNS.
miR-219 Treatment Reduces Proinflammatory Cytokine Levels
To further examine changes in immune responses in infected mice,
levels of proinflammatory cytokines were determined by multiplex
ELISA in spinal cord protein extracts. Interleukin-10 (IL-10), IL-4,
CXCL1, IL-1b, and tumor necrosis factor alpha (TNF-a) were signif-
icantly reduced in infected mice treated with miR-219 compared to
vehicle and/or scrambled miR controls (Figures 6A–6C, 6G, and
6J), respectively, whereas levels of interferon-g (IFN-g), IL-2, and
IL-6 did not change in treatedmice (Figures 6D–6F). ELISA and west-
ern blot analysis of IL-1b signaling, which has been proposed to
protect and promote demyelination during infection,30 indicated sig-
nificant recovery of IL-1b activation in miR-219-treated mice, return-
ing levels to that of uninfected controls (Figures 6H and 6I). Levels of
activated TNF-a (Figure 6K and 6L), important for apoptosis during
infection,31 were not normalized after treatment. Together, these re-
sults further support the beneficial role of miR-219 on gliosis and
inflammation in the TMEV model.) Sensorimotor functions analyzed by hot plate (K) and tape test (L): latency (sec) to
) = 7.66 and (J) F (3, 20) = 15.19, *p < 0.05, **p < 0.01, and ***p < 0.001. All tests
V+veh), scrambled miR (TMEV+miR-scr), or miR-219 (TMEV+miR-219). Data are
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Figure 3. Treatment with miR-219 Reduces TMEV-Mediated Demyelination
(A and B) Representative micrographs of dorsal (A) and ventral (B) white matter in thoracic segments of the spinal cord; scale bar, 20 mm. (C–F) Demyelinated axons (% total
axons) and myelin thickness (g ratio) were quantified in dorsal (C and E) and ventral (D and F) white matter from thoracic segments of the spinal cord; one-way ANOVA
followed by Tukey’s test: (C) F (3, 27) = 157.1, (D) F (3, 29) = 44.5, (E) F (3, 850) = 81.4, and (F) F (3, 797) = 16.4, *p < 0.05, **p < 0.01, and ***p < 0.001. (C–F) n = 3 per group.
(G) Representative micrographs of Luxol fast blue and cresyl violet staining of thoracic segments of the spinal cord show demyelinated areas (solid line) relative to total white
matter (WM) (dashed line); scale bar, 100 mm. (H) Quantification of demyelinated areas by Luxol fast blue and cresyl violet staining; one-way ANOVA followed by Tukey’s test,
F (3, 32) = 10.45, *p < 0.05 (n = 4 per group). Experimental groups: controls (Ct) and mice with chronic demyelination treated with vehicle (TMEV+veh), scrambled miR
(TMEV+miR-scr), or miR-219 (TMEV+miR-219). Data are expressed as the mean ± SEM.
Molecular TherapymiR-219 Potentiates Downregulation of Cholesterol-Related
Genes
Tocompile a profile of transcriptional changes aftermiR-219 treatment,
spinal cords were analyzed for expression of host genes by RNA
sequencing. Although BeAn virus infection has consistently shown bio-
logical variability between experimental groups,7 hierarchical clustering
of gene expression pointed to two different groups of genes in infected
mice (Figure S3A). GO functional enrichment analysis showed that for
all groups, changesweremostly associatedwith immune biological pro-734 Molecular Therapy Vol. 26 No 3 March 2018cesses (GEO:GSE107091;Table S1). These transcriptswere upregulated
in infected mice compared to healthy controls (see top segment of clus-
ter 2 of the heatmap in Figure S3A), whereas a separate group of genes
(cluster 1), primarily involved in cholesterol biosynthesis and synaptic
vesicle trafficking, was substantially downregulated in miR-219-treated
mice (Figure S3B). Comparison of genes from cluster 1 with a list of
miR-219-predicted targets by Targetscan32 showed that 4 of 388 pre-
dicted gene targetswere present in cluster 1, includingCyp51 (lanosterol
14-a demethylase) and Insig1 (insulin-induced gene 1) (Figure S3C;
Figure 4. Treatment with miR-219 Improves Myelination in TMEV-Infected Mice
(A–D) Confocal microscopy quantitative analysis of MBP (myelin, green) and NeuN (neurons, red) (A and B) and of CC1 (OLs, red, arrowheads) (C and D) in thoracic spinal
cord sections. Background staining controls of anti-mouse Alexa 546/anti-rabbit Cy5 and control anti-mouse Alexa 546 are shown. Nuclei were stained with DAPI (blue);
scale bar, 20 mm. One-way ANOVA followed by Tukey’s test, F (3, 151) = 11.11, *p < 0.05 and **p < 0.01 (n = 4 per group). (E and F) Western blot analysis of MBP levels in
protein extracts from the thoracic spinal cord (E); one-way ANOVA followed by Tukey’s test (F), F (3, 23) = 11.01, *p < 0.05 and **p < 0.01 (n = 7 to 8 per group). (G and H)
Pdgfra+ cells were counted after RNA in situ hybridization (G); scale bar, 40 mm; one-way ANOVA followed by Tukey’s test (H), F (3, 97) = 9.97, *p < 0.05 (n = 4 per group).
(I and J) Western blot analysis of PDGFRa levels in protein extracts from the thoracic spinal cord (I); one-way ANOVA followed by Tukey’s test (H), F (3, 28) = 16.25, *p < 0.05
and **p < 0.01 (n = 7 to 8 per group). (K and L)Olig2+ cells were counted after RNA in situ hybridization (n = 4 per group); scale bar, 40 mm. Experimental groups: controls (Ct)
and mice with chronic demyelination treated with vehicle (TMEV+veh), scrambled miR (TMEV+miR-scr), or miR-219 (TMEV+miR-219). Data are expressed as the
mean ± SEM.
www.moleculartherapy.orgTable S1), which play essential roles in cholesterol biosynthesis.33,34
qPCR analysis showed that Cyp51 and Hmgcs1 were both significantly
reduced in mice treated with miR-219 relative to mice treated with
vehicle or scrambled miR (Figures 7A and 7B). Srebf1, a master regu-
lator of cholesterol biosynthesis,35 was also significantly reduced by
miR-219 (Figure 7C), whereas there were no significant differences
for Insig1, Hmgcr, and Srebf2 between the groups (Figures 7D–7F).
Genes associated with cholesterol biosynthesis affected in infected
mice treated with miR-219 (Figure S3) were not downregulated in
normal non-infected OPCs or OLs after miR-219 treatment13 (GEO:
GSE80439) (Figures S4A and S4B). These findings indicate that in the
context of BeAn virus infection, beneficial effects from miR-219 treat-
ment were associated with transcriptional changes in genes related to
cholesterol biosynthesis.miR-219 Decreases Cholesterol Levels
Inhibition of cholesterol biosynthesis has been shown to promote
anti-viral immunity,36 and, like other picornaviruses, BeAn virus
replicates in remodeled intracellular membranes (viroplasm) by hi-
jacking cholesterol trafficking and altering host lipid homeostasis.17,37
Spectrofluorometric analysis to test whether downregulation of
cholesterol-related genes was associated with changes in cholesterol
levels revealed a significant reduction in cholesterol levels in the
thoracic segment of the spinal cord of miR-219-treated mice
compared to controls (Figure 8A). Similar results were observed
with filipin staining of spinal cord sections by confocal microscopy
(Figure 8B). Although changes in cholesterol after infection may be
due in part to chronic demyelination, miR-219-treated mice showed
less demyelination and significant reduction in cholesterol. To testMolecular Therapy Vol. 26 No 3 March 2018 735
Figure 5. miR-219 Reduces Astrogliosis, Microglia Activation, BeAn Copy Numbers, and Immunoreactivity
(A) Astrogliosis was analyzed by western blotting of Serpina3n and GFAP in protein extracts from the thoracic spinal cord: (B) one-way ANOVA followed by Tukey’s test,
F (3, 21) = 47.47, *p < 0.05 and ***p < 0.001 (n = 5–8 per group); and (C) one-way ANOVA followed by Tukey’s test, F (3, 21) = 17.03, ***p < 0.001 (n = 5–7 per group). (D)
Microglia was quantified by confocal microscopy in thoracic segments of spinal cords; one-way ANOVA followed by Tukey’s test, F (3, 108) = 29.83, *p < 0.05 and
***p < 0.001 (n = 4 per group). (E) BeAn copy number by qPCR; one-way ANOVA followed by Tukey’s test, F (3, 26) = 7.62, *p < 0.05 (n = 7 to 8 per group). (F) BeAn capsid
staining was quantified by confocal microscopy; one-way ANOVA followed by Tukey’s test, F (2, 72) = 19.15, **p < 0.01 and ***p < 0.001 (n = 4 per group). Experimental
groups: control (Ct) and mice with chronic demyelination treated with vehicle (TMEV+veh), scrambled miR (TMEV+miR-scr), or miR-219 (TMEV+miR-219). Data are
expressed as mean ± SEM.
Molecular Therapywhether miR-219 reduced cholesterol biosynthesis, differentiated
CG-4 cells infected with BeAn virus (10 MOI), in the presence or
absence of miR-219, were analyzed for cell viability and cholesterol
levels. Cells treated with miR-219 showed a significant increase in
viability compared to those treated with vehicle (Figures 8C and
8D), and depletion of cholesterol with methyl-b-cyclodextrin
(MBCD) before infection showed similar results to those observed
in miR-219-treated cells. Cholesterol levels in cells treated with
miR-219 and MBCD were substantially reduced compared to those
treated with vehicle or miR-scrambled, even at 24 hr pi (Figure 8E).
Although primary OL and astrocyte cultures are less susceptible to
TMEV infection in vitro,38 cholesterol levels were substantially
reduced in those cells treated with miR-219 before infection
compared with scrambled miR-treated cells (Figure 8F). Thus,
miR-219-induced changes in cholesterol biosynthesis may limit its
availability for formation of membranes and active replication of
TMEV, affecting virus RNA replication and alleviating viral effects
on infected mice.
DISCUSSION
Dysregulated miRs associated with different diseases can be corrected
by rescue or inhibition using miR-based therapies. Here, we tested
whether rescue of miR-219 in the BeAn virus infection is therapeutic.
Indeed, treatment with miR-219 reduced virus-induced demyelin-736 Molecular Therapy Vol. 26 No 3 March 2018ation and clinical disease progression based on recovery of sen-
sorimotor function, reduction of the CNS inflammatory response,
and virus load. Transcriptional analysis showed that miR-219 down-
regulates cholesterol-related genes and lowers cholesterol levels in the
CNS. Note that reduction of available cholesterol is a strategy to inter-
fere with the life cycle of many RNA viruses.17,39 However, we find
that in the context of virus-induced demyelination, miR-219 shows
additional physiological functions beyond its therapeutic effects in
myelin repair.
During normal CNS myelination, miR-219 induces OL maturation by
inhibiting neuronal differentiation from early undifferentiated neural
precursors via repression of NeuroD1 and Zfp238 and by facilitating
maturation of committed OPCs into mature OLs by repressing several
key genes, including Pdgfra, Hes5, Sox6, Etv5, and Lingo1.11–13 Our
recent gain- and loss-of-function studies identified an additional role
for miR-219 in remyelination during lysolecithin- and EAE-induced
demyelination.13 In both chemical and immunologic-demyelinating
paradigms, the pro-remyelinating properties of miR-219 were medi-
ated by canonical repression of Pdgfra expression in OPCs, driving
OLmaturation.13 Similarly, lentiviral expressionofmiR-219 and trans-
plantation of OPCs overexpressing miR-219 promoted remyelination
and functional recovery after cuprizone-induced demyelination.15,16
Here, we find an overall improvement in demyelination and
Figure 6. miR-219 Reduces Proinflammatory Cytokines and Restores IL-1b Activation
Quantitation of IL-10 (A), IL-4 (B), CXCL1 (C), IFN-g (D), IL-2 (E), IL-6 (F), IL-1b (G), and TNF-a (J), respectively, in thoracic spinal cords analyzed by a multiplex ELISA: MSD
proinflammatory panel; one-way ANOVA followed by Tukey’s test: IL-10 F (3, 17) = 32.62, IL-4 F (3, 16) = 14.95, CXCL1 F (3, 11) = 11.12, IFN-g F (3, 19) = 18.43, IL-2 F
(3, 22) = 8.16, IL-6 F (3, 19) = 26.23, IL-1b F (3, 18) = 59.66, and TNF-a F (3, 18) = 19.41, *p < 0.05, **p < 0.01 and ***p < 0.001 (n = 5–7 per group). (H and I) Representative
Western blot of active (17 KDa) and total (31 KDa) IL-1b expression (H) and band analysis of activated IL-1b normalized to the total protein (I). One-way ANOVA followed by
Tukey’s test F (3, 21) = 13.94, ***p < 0.001 (n = 6–7 per group). (K and L) Representative Western blot of active (17 KDa) and total (25 KDa) TNF-a expression (K) and band
analysis of activated TNF-a normalized to total protein levels (L). Experimental groups: control (Ct) and mice with chronic demyelination treated with vehicle (TMEV+veh),
scrambled miR (TMEV+miR-scr) or miR-219 (TMEV+miR-219). Data are expressed as the mean ± SEM.
www.moleculartherapy.orgneurological function in infectedmice through the anti-viral activity of
miR-219. Potential miR-219-based therapies require extensive studies
to improve specificity40 and determine the therapeutic window for
demyelinating diseases and virus-induced encephalomyelitis. Further
studies are also needed to evaluate off-target gene silencing and poten-tial side effects to avoid a deleterious outcome in the endogenous pro-
cess of remyelination41 and anti-viral immune response.
Picornaviruses such as TMEV replicate their RNA on host virus-re-
modeled membranes, termed viroplasm or replication organelles.37,42Molecular Therapy Vol. 26 No 3 March 2018 737
Figure 7. miR-219 Potentiates Transcriptional
Changes in Cholesterol-Related Genes
(A–F) qPCR validation of genes from cluster 1 (see also
Figures S3A and S3B) that are involved in cholesterol
biosynthesis Hmgcs1: hydroxymethylglutaryl-CoA syn-
thase (B), Srebf1: esterol regulatory element-binding pro-
tein 1 (C),Hmgcr: 3-hydroxy-3-methylglutaryl-coenzymeA
reductase (E), and Srebf2: esterol regulatory element-
binding protein 2 (F) and are also predicted targets of
miR-219 (Cyp51: lanosterol 14-a demethylase, A, and
Insig1: insulin-inducedgene1protein,D); one-wayANOVA
followed by Tukey’s test: Hmgcs1, F (3, 25) = 39.02;
Srebf1, F (3, 26) = 6.14; Hmgcr, F (3, 27) = 24.91; Srebf2,
F (3, 29) = 5.45; Cyp51, F (3, 23) = 77.44; and Insig1,
F (3, 27) = 59.09; *p < 0.05, **p < 0.01, and ***p < 0.001
(n = 5–8 per group). Experimental groups: control (Ct) and
mice with chronic demyelination treated with vehicle
(TMEV+veh), scrambledmiR (TMEV+miR-scr), ormiR-219
(TMEV+miR-219). Data are expressed as mean ± SEM.
Molecular TherapyCholesterol is a key component of these organelles, and dysregulation
of its biosynthesis or trafficking negatively impacts virus RNA repli-
cation.17,39 Cholesterol-related genes, which were initially believed to
play a role in inhibiting remyelination,43 were found to be downregu-
lated in infected mice, consistent with our RNA sequencing analysis
showing that BeAn virus decreased expression of a cluster of genes
involved in cholesterol biosynthesis. Unexpectedly, treatment with
miR-219 potentiated these changes, with a further decrease in choles-
terol levels in the spinal cord by miR-219-mediated downregulation
of Cyp51, Hmgcs1, and Srebf1. By repressing cholesterol synthesis,
miR-219 negatively regulated sustained virus RNA replication, lead-
ing to lower virus load, less demyelination, and amelioration of
clinical disease. Thus, cholesterol-based therapies aimed to improve
remyelination would not be as regenerative as expected,44 despite
the importance of cholesterol in myelin biogenesis.45,46 Analysis of
cells after in vitro depletion of cholesterol with MBCD confirmed
that reduction of cholesterol leads to a protective effect similar to
that observed with miR-219. Treatment with miR-219 more likely
potentiated downregulation of genes involved in cholesterol biosyn-
thesis in the context of TMEV infection because control experiments
using non-infected OPCs and OLs treated with miR-219 did not show
downregulation of these genes.
Changes in cholesterol biosynthesis affect anti-viral immunity by
regulating the type I IFN response,36 and chronic immune activa-
tion of IFN facilitates virus persistence.47,48 We found that
miR-219 treatment reduced the levels of IFN-g, IL-4, IL-10, and
CXCL1, while activating IL-1b, indicating highly selective effects
on cytokine production. The mRNA levels of Srebf1 were normal-
ized after miR-219 treatment, and have been associated with
IFN-mediated anti-viral responses by regulating IL-1b in inflam-
mation.49–51 Reduced inflammation likely reflects reduced virus
RNA replication and reduced microglial activation and astro-
gliosis and a more competent blood-brain barrier. Clearly,
miR-219 exerts pleiotropic effects on virus load and proinflamma-738 Molecular Therapy Vol. 26 No 3 March 2018tory cytokines, ultimately leading to less demyelination and disease
severity.
Together, our findings indicate that miR-219 induces beneficial ef-
fects in TMEV-infected mice, restoring neurological function and
reducing virus-induced encephalomyelitis. These effects of miR-219
likely reflect its pro-remyelinating properties, the changes in the
virus life cycle it induces by downregulating cholesterol-related genes,
and the reduced availability of cholesterol to form replication organ-
elles to sustain virus persistence. The specificity of these effects for
miR-219 in BeAn virus infection is currently unclear but could be
relevant to other viruses because several miRs play anti-viral roles
in a wide spectrum of viral infections.5,52–54 Overall, our study points
to the promise of RNA-based therapies as an approach to reduce vi-
rus-induced demyelination, manipulation of the host response to vi-
rus infections, and impact virus persistence.
MATERIALS AND METHODS
Virus Culture
BHK-21 cells were grown in DMEM supplemented with 10% fetal
bovine serum (FBS), 7.5% tryptose phosphate, 2 mM L-glutamine,
100 U/mL penicillin, and 100 mg/mL streptomycin at 37C in a 5%
CO2 atmosphere. BeAn virus was amplified in BHK-21 cells and
the titer of the virus stock was 2  109 plaque-forming unit
(PFU)/mL. The origin and passage history of BeAn virus have been
described.55
TMEV Inoculation in Mice and Tissue Processing
All animal procedures were approved by the Institutional Animal
Protection Committee at the University of Illinois at Chicago. SJL
female mice (4–6 weeks old) were obtained fromHarlan Laboratories.
Mice were anesthetized and injected into the right cerebral
hemisphere with 2 mL DMEM or DMEM containing 2  106
PFU/inoculum. Mice were allowed to recover and treated with
miRNAmimics or vehicle at 28 days post-infection (dpi) (see below).
Figure 8. miR-219 Reduces Cholesterol Levels In Vivo and In Vitro
(A) Cholesterol levels by the Amplex Red Cholesterol assay in thoracic spinal cords; one-way ANOVA followed by Tukey’s test, F (2, 21) = 10.44, *p < 0.05 and ***p < 0.001
(n = 6 to 7 per group). (B) Filipin (cholesterol) was measured after staining and analysis by confocal microscopy in thoracic spinal cord; one-way ANOVA followed by Tukey’s
test, F (2, 66) = 4.05, *p < 0.05 (n = 4 per group). Experimental groups: control (Ct) and mice with chronic demyelination treated with vehicle (TMEV+veh), scrambled miR
(TMEV+miR-scr), or miR-219 (TMEV+miR-219). (C and D) Micrographs of neuroglial CG-4 cells (C) and cell viability (WST-1 assay) (D), respectively, of CG-4 cells at 24 hr after
TMEV infection (10 MOI) in differentiating conditions (3 div) treated with vehicle (TMEV+veh), scrambled miR (TMEV+miR-scr), miR-219 (TMEV+miR-219), or MBCD (1.5 mM)
before infection; scale bar, 40 mm; one-way ANOVA followed by Tukey’s test, F (3, 13) = 9.08, **p < 0.01 (n = 3–6 per group). (E) Cholesterol levels measured by the Amplex
Red Cholesterol assay in CG4 cells from (D). (F) Cholesterol levels by the Amplex Red Cholesterol assay of OL (n = 2) and astrocytes (n = 3) treated with miR-219 before TMEV
infection. Student’s t test, t(4) = 5.55, **p = 0.005. Data are expressed as mean ± SEM.
www.moleculartherapy.orgFor tissue collection, mice were anesthetized and perfused with phos-
phate buffer (0.2 M, pH 7.4). The right brain hemisphere and half of
the cervical, thoracic, and lumbar spinal cords were post-fixed in 4%
paraformaldehyde (PFA) overnight before processing for immuno-
histochemistry. The left-brain hemisphere and half of the cervical,
thoracic, and lumbar spinal cords were immediately frozen for
biochemical and transcriptional analyses. For immunohistochem-
istry, 30- to 40-mm sections were cut on a Leica SM2010 R sliding
microtome and cryopreserved at 20C in 30% glycerol and 30%
ethylene glycol in 20 mM phosphate buffer until further use.Intranasal Administration of miRNA Mimics
miRNA mimics (Life Technologies) were mixed with transfection re-
agent i-Fect (Neuromics) at a ratio of 1:5 (w/v). Mice were treated
with vehicle (i-Fect without mimics), scrambled miR (negative
control #1, 4464059), or miR-219 (50-UGAUUGUCCAAACGCAAU
UCU-30, 4464066 assay ID: MC10664) with i-Fect (2 mg miRNA).
Intranasal delivery was completed over a 20-min period at a rate of
2 mL/min to alternating nostrils in slightly anesthetized animals. After
22 weeks (182 dpi) of supplementation with miRNA mimics, mice
were euthanized and dissected for tissue processing.Clinical Score and Behavioral Tests
Assessment of clinical score and behavioral experiments were per-
formed in standard animal room housing after 6 weeks (4-month-
old mice) or 22 weeks (8-month-old mice) of treatment. Clinical
scores: 1, mild waddling gait; 2, more severe waddling gait with
extensor spams; and 3, lack of righting ability. Body weight loss: 0.5
(0.1–0.5 g); 1 (0.5–1 g); 1.5 (1–2 g), and 2 (>2 g). Cumulative clinical
scores were calculated as the sum of the clinical and body weight loss
scores. Sensorimotor functions were assessed at different time points
of miRNA supplementation by the following behavioral tests.
Clasping score: mice were held by their tails, observed for hindlimb
position for 10 s, and scored as 0 (splayed out); 1 (retracted toward
abdomen <5 s); 2 (retracted toward the abdomen >5 s); and 3 (entirely
retracted and touching the abdomen >5 s). Hot plate test: mice were
placed on a hot plate (52C–55C) enclosed by a compartment; la-
tency for paw withdrawal was measured, with a cutoff time set to
10 s to avoid tissue damage. Tape test: a rectangular strip of tape
was placed on the forepaws of mice and the time between contact
of the mouse with the surface of the cage and either shaking its
paws and/or directly bringing its paws to its mouth was measured.
Rotarod test: after mice completed 3 days of training (3 sessions of
5 min each, accelerating from 4 to 40 rpm over 5 min) in an in-houseMolecular Therapy Vol. 26 No 3 March 2018 739
Molecular Therapybuilt apparatus, a test trial was performed after 6 or 22 weeks of
miRNA supplementation. Footprint analysis: mice with forelimb
and hindlimb paws painted with red and blue nontoxic paint, respec-
tively, were placed at the start of a cardboard walkway (90-cm long,
6-cm wide, and 15-cm high) and expected to walk along a strip of
standard white paper. Prints were analyzed by measurements of
stride, sway, and stance between steps for a minimum of 4 steps.
The results of each behavioral test were averaged within each exper-
imental group.
Nerve Conduction Studies
Mice were anesthetized and the sciatic nerve was exposed. Stimula-
tion was delivered via dual gold needle electrodes to the sciatic nerve
and action potentials were recorded on an iWorx 228S Recorder,
with a 5-lead electrocardiography (ECG)/electroencephalogram
(EEG)/electromyography (EMG) cable within the gastrocnemius
muscle.
Immunohistochemistry and Imaging
Tissue sections were blocked with 1% BSA, 10% donkey serum, 1%
gelatin 0.3 M glycine, and 0.4% Triton X-100 in PBS for 1 hr at
25C and incubated with the following primary antibodies for 72 hr
at 4C: PDGFRa 1:200 (Cell Signaling, 3164 and 3174); anti-Olig2
1:200 (Millipore, MABN50); CC1 1:50 (Millipore, OP80); MBP
1:1,000 (generous gift of Dr. Anthony Campagnoni, UCLA; rabbit
polyclonal); NeuN 1:200 (Millipore, MAB377); GFAP 1:2,000 (Milli-
pore, MAB3402); NG2 1:200 (Millipore, MAB5384); Iba1 1:1,000
(Wako, 019-19741), fibrinogen 1:200 (Agilent-Dako, A0080); and
TMEV 1:2,000 (rabbit polyclonal). After washing 3 times in PBS, sec-
tions were incubated with the corresponding secondary antibody for
24 hr at 4C: goat anti-mouse IgG (H+L); Alexa Fluor 546 1:1,000
(Life Technologies, A-11030); or Cy-2 IgG fraction monoclonal
mouse anti-rabbit IgG (light chain-specific) 1:1,000 (Jackson Immu-
noResearch, 211-222-171); and were covered with mounting media
containing DAPI (Invitrogen, P36931). For cholesterol analysis, sec-
tions incubated with 50 mg/mL filipin (Polysciences, 08707) were
incubated with To-pro-3 (Thermo Fisher Scientific, T3605). Fluores-
cence images were acquired with a Zeiss LSM 710 confocal micro-
scope and quantified by ImageJ (NIH). RNA in situ hybridization
was performed using digoxigenin-labeled Pdgfra riboprobes as
described.12
Luxol Fast Blue Myelin Staining
Tissue sections were stained with 0.1% Luxol fast blue solution (96%
ethanol and 0.5% acetic acid) for 24 hr at 60C, washed consecutively
with 90% ethanol, ddH2O, and 0.05% Li2CO3, and stained with 0.1%
cresyl violet. Images were acquired with an automated Leica
DM5500 B upright microscope, and areas of demyelination were
quantitated using Image-J software for morphometric measurements.
G-ratio analysis
Tissue sections were fixed in electron microscopy fixative of 4% PFA
and 2% glutaraldehyde. Tissue sections were post-fixed in 1% OsO4,
dehydrated with ethanol, and embedded in Epon 812. Transverse740 Molecular Therapy Vol. 26 No 3 March 2018semithin (1-mm) sections through the cervical cords were stained
with Toludine blue. Images were acquired with an automated Leica
DM5500 B upright microscope and quantified using ImageJ software.
Myelin thickness (g ratio) was quantified as axon diameter/axon +
myelin diameter (100 axons per anatomical region  dorsal and
ventral white matter per animal; n = 3 mice per group).
Western Blotting
Tissue lysates were prepared and normalized to a protein content of
20 mg per sample by BCA assay (Pierce) and subjected to SDS poly-
acrylamide gel electrophoresis (4%–12%) using the XCell Sure-lock
vertical electrophoresis system (Invitrogen). Gels were transferred
to PVDFmembranes, blocked with 5%milk in 0.1% Tris-buffered sa-
line (TBS)-Tween 20 solution, and incubated for 24 hr at 4Cwith the
following primary antibodies: MBP 1:5,000 (rabbit polyclonal); actin
1:2,000 (Sigma, A2066); PDGFRa 1:1,000 (Cell Signaling, 3164 and
3174); anti-Olig2 1:500 (Millipore, MABN50); GFAP 1:2,000 (Milli-
pore, MAB3402); Serpina3n 1:2,000 (R&D systems, AF4709); IL-1b
(Abcam, ab9722); and TNF-a 1:500 (Cell Signaling, 3707). Incuba-
tion with secondary antibodies, anti-rabbit 1:1,000 (Cell Signaling,
7074), or anti-mouse 1:1,000 (Cell Signaling, 7076) was performed
for 1 hr at 25C, and membranes were developed using ECL (Pierce)
and quantified using ImageJ software.
Amplex Red Cholesterol Assay
Cholesterol levels in cell or spinal cord homogenates (1–2 mL) were
measured in 96-well plates using the fluorometric Amplex Red
cholesterol assay kit according to the manufacturer’s instructions
(Invitrogen). Fluorimetric analysis was performed using a Beckman
Coulter DTX 880 multimode detector (Molecular Devices).
Multiplex Cytokine ELISA
Thoracic spinal cord section homogenates in PBS (1:10 w/v) with
mammalian protease inhibitor cocktail were sonicated and 1% Triton
X-100 was added and incubated for 30min at 4C in an orbital shaker.
After centrifugation at 12,000  g for 20 min at 4C, protein in each
supernatant was quantified (BCA assay) and samples (150 mg protein)
were analyzed using the V-PLEX Proinflammatory Panel 1 kit from
Meso Scale Discovery (MSD) per the manufacturer’s instructions in
an MSD Sector Imager 2400.
RNA Extraction and qRT-PCR
Total RNA (including small RNAs)was purified from tissues or cell cul-
tures using the miRVana miRNA isolation kit per the manufacturer’s
instructions (Life Technologies). RNA was transcribed to cDNA with
the iScript cDNASynthesis kit (Bio-Rad), andqRT-PCRwasperformed
using the IQ5 real-time PCR detection system (Bio-Rad). Relative gene
expressionwas normalized toGapdh. qPCRprimerswereHmcgs1: For-
ward: 50-AACTGGTGCAGAAATCTCTAGC-30, Reverse: 50-GGTTG
AATAGCTCAGAACTAGCC-30, Hmgcr: Forward: 50-AGCTTGCCC
GAATTG-TATGTG-30, Reverse: 50-TCTGTTGTGAACCATGTGA
CTTC-30, Cyp51: Forward: 50-GACAGGAGGCAACTTGCTTTC-30,
Reverse: 50-GTGGACTTTTCGCTCCAGC-30, Insig1: Forward: 50-TC
ACAGTGACTGAGCTTCAGCA-30, Reverse: 50-TCATCTTCA-TCA
www.moleculartherapy.orgCACCCAGGAC-30, Srebf2: Forward 50-GCAGCAACGGGACCAT
TCT-30, Reverse 50-CCCCATGACTAAGTCCTTCAACT-30, Srebf1:
Forward: 50-GATGTGCGAACTGG-ACACAG-30, Reverse: 50-CATA
GGGGGCGTCAAACAG-30, and Gapdh: Forward: 50-AGGTCGGTG
TGAACGGATTTG-30, Reverse: 50-TGTAGACCATGTAGTTGAGG
TCA-30.
To analyze miRNA expression, RNA samples were transcribed using
the TaqMan MicroRNA Reverse Transcription kit (Applied Bio-
systems) and real-time PCR was performed on a ViiA 7 Real-Time
PCR System (Applied Biosystems). Relative gene expression was
normalized to U6. Applied Biosystems qPCR primers were: Assay
ID: 002252 - Name: hsa-miR-338-3p, Assay ID: 000522 - Name:
hsa-miR-219, Assay ID: 002284 - Name: hsa-miR-138, Assay ID:
001097 - Name: hsa-miR-146b, Assay ID: 000396 - Name: hsa-
miR-19b, and Assay ID: 002308 - Name: hsa-miR-17.
RNA Sequencing and Data Analysis
RNA isolated from spinal cords was analyzed byNext-Generation RNA
Sequencing (Illumina). Raw reads were aligned to the reference genome
using BWA MEM,56 which efficiently maps reads with read-through
into polyA tails and adaptor sequences, as is commonwith 30 RNA-seq.
Gene expression levels were quantified using FeatureCounts,57 first as
raw read counts suitable for differential expression analyses, and also
normalized to reads-per-million for direct comparison between sam-
ples. Differential expression statistics (fold-change and p value) were
computed using edgeR58,59 on raw expression. Both multi-group tests
between all experimental groups and pairwise tests between pairs of
groupswereperformed,withp values adjusted formultiple testingusing
the false-discovery rate (FDR) correction of Benjamini andHochberg60
in all cases. Significant genes were identified based on an FDR threshold
of 5%(0.05).GOanalysis of geneswasperformedusingGOConsortium
(http://www.geneontology.org). RNA-seq data have been deposited in
the NCBI Gene Expression Omnibus (GEO). GEO: GSE107091. OPC
and OL gene expression levels were obtained at the NCBI GEO data-
base,61 GEO: GSE8043913 (see also Table 1).
Cell Culture and Transfection
CG-4 rat glial progenitor cells grown in DMEM/F12 (Gibco,
11330-032) supplemented with mitogens 10 ng/mL, PDGF-AA
(Prepotech, 100-13A), and 5 ng/mL bFGF (Prepotech, 100-18B)62
were allowed to differentiate for 1 or 3 days in vitro (1 days in vitro
[div] or 3 div) in OL differentiation medium.63 miRNA transfection
was carried out with i-Fect using miRNA mimics at 50 nM. Neural
stem cells were isolated from the telencephalon of 16-day SJL mouse
embryos and maintained as neurospheres in suspension culture in
medium containing 10 ng/mL bFGF and 20 ng/mL EGF (Prepotech,
AF-100-15). Neurospheres were grown in NeuroCult basal medium
(STEMCELL Technologies, 05700) under proliferative conditions
(proliferation supplement, 05701) for 3–7 days, harvested, collected
by centrifugation, suspended and mechanically dissociated,
and maintained under proliferation or differentiation conditions
(STEMCELL Technologies differentiation supplement, 05703).
Mixed glial cultures were obtained as described,64 with minor modi-fications.63 Cortices were isolated frommouse pups (P2–P4) and glial
cells were cultured in medium supplemented with 10% FBS (Atlanta,
S11595H) for 14 to 15 days. After enrichment, astrocytes were grown
in FBS-supplemented media and OL in specific medium63 for
7–9 days. BHK-21 cells were grown in DMEM supplemented with
10% FBS, 7.5% tryptose phosphate (MP biomedicals, 091682149),
and 2 mM L-glutamine (GIBCO, 25030149).In Vitro Virus Infection and Cholesterol Depletion
CG-4 cells were washed twice with Dulbecco’s PBS and infected at an
MOI of 1, 5, and 10 at 24C for 45 min in serum-free medium, with
rocking every 10min to allow virus adsorption. Cells were maintained
thereafter in fresh virus-free culture medium for 24 hr. For cholesterol
depletion, cells were treated for 1 hr with 1.5 mM of methyl-
b-cyclodextrin (Sigma, C4555) in DMEM/F12 supplemented with
25 mM HEPES before infection.Cell Viability Assay
WST-1 reagent (Roche) was added to the medium of monolayer cul-
tures and incubated at 37C in 5% CO2 for 2–4 hr. Cell viability in
samples was determined by absorbance at 420 nm (reference wave-
length, 610 nm) against a background control (medium) using a mi-
croplate reader (Molecular Devices). Cell viability was calculated as
the ratio of BeAn virus-infected to mock-infected cultures.Statistical Analyses
Each experimental condition was tested at least in duplicate, and an-
imal studies utilized 7 or 8 mice per experimental group. Data were
analyzed using one-way ANOVA followed by Dunnett’s multiple
comparison test or Tukey’s post hoc test or two-way ANOVA fol-
lowed by Bonferroni’s post hoc test where appropriate. p values < 0.05
were considered significant. Data were analyzed using GraphPad
Prism 6.00 (San Diego, CA, https://www.graphpad.com). Results
are shown as the mean ± SEM, with horizontal bars representing
significant differences between miR-219-treated infected mice
compared to the rest of the experimental groups.SUPPLEMENTAL INFORMATION
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